Nanobac Pharmaceuticals Profit Margin

Nanobac Pharmaceuticals posts a profit margin of -37319.74% as of December 2007. That compares with -2209.53% in the prior-year period — down 1589.0% year over year. That is below the Healthcare sector average of 15.29%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Nanobac Pharmaceuticals's profit margin was -2209.53%. The latest reading is -37319.74% — a 1589.0% year-over-year decrease (period ending December 2007). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 15.29% is typical. Nanobac Pharmaceuticals's -37319.74% is lower that level. That is roughly 244133.3% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Nanobac Pharmaceuticals's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -37319.74% as of December 2007; use YoY and peer views to separate noise from signal.

Context for NNBP's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 15.29%), and (3) consistency with growth and profitability. This page covers the first two; Nanobac Pharmaceuticals's other metric pages and overview cover the third.